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Purpose: Smooth muscle dysfunction syndrome (SMDS) due to
heterozygous ACTA2 arginine 179 alterations is characterized by patent
ductus arteriosus, vasculopathy (aneurysm and occlusive lesions),
pulmonary arterial hypertension, and other complications in smooth
muscle–dependent organs. We sought to define the clinical history of
SMDS to develop recommendations for evaluation and management.
Methods: Medical records of 33 patients with SMDS (median age 12
years) were abstracted and analyzed.
Results: All patients had congenital mydriasis and related pupillary
abnormalities at birth and presented in infancy with a patent ductus
arteriosus or aortopulmonary window. Patients had cerebrovascular
disease characterized by small vessel disease (hyperintense periven-
tricular white matter lesions; 95%), intracranial artery stenosis (77%),
ischemic strokes (27%), and seizures (18%). Twelve (36%) patients
had thoracic aortic aneurysm repair or dissection at median age of 14
years and aortic disease was fully penetrant by the age of 25 years.
Three (9%) patients had axillary artery aneurysms complicated by
thromboembolic episodes. Nine patients died between the ages of 0.5
and 32 years due to aortic, pulmonary, or stroke complications, or
unknown causes.
Conclusion: Based on these data, recommendations are provided
for the surveillance and management of SMDS to help prevent early-
onset life-threatening complications.
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INTRODUCTION
Smooth muscle dysfunction syndrome (SMDS, MIM 613834)
presents with a recognizable pattern of complications,
including congenital mydriasis, patent ductus arteriosus
(PDA), pulmonary arterial hypertension, aortic and other
arterial aneurysms, moyamoya-like cerebrovascular disease,
intestinal hypoperistalsis and malrotation, and hypotonic
bladder.1 It is caused by heterozygous mutations of the
ACTA2 altering arginine 179, most commonly p.Arg179His.
With a single exception, all cases are due to de novo
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mutations. Seven SMDS cases were initially reported,1
followed by reports of cases with similar presentation and
additional complications often resulting in poor health
outcomes and early deaths.2–13
The clinical evolution of the recently identified SMDS has
not been described and guidelines for evaluation and medical
management are lacking. Therefore, we sought to describe the
clinical history and outcomes of SMDS patients. These data
are used as a basis to propose guidelines for clinical evaluation
and management of patients with SMDS and direct future
therapeutic trials.
MATERIALS AND METHODS
The study was approved by the institutional review board of
the University of Texas Health Science Center at Houston,
and informed consent was obtained from the participants or
parents. Outside investigators provided de-identified patient
data after obtaining approval from their respective institu-
tional review boards and consent from the patient or family.
Thirty-three patients with confirmed mutations of the
ACTA2 Arg179 from North America, Europe, Asia, and
Australia were enrolled from 2009 to 2017. Medical informa-
tion were collected through review of available medical
records (Supplemental Information online). All reported
data reflected the patient’s diagnosed medical conditions and
treatment at the last clinical evaluation.
Data were analyzed using STATA/IC version 12.1 (College
Station, TX). Categorical variables were summarized by
frequency and percentage and continuous variables by
median, interquartile range (IQR), minimum/maximum
values. Failure functions of clinical endpoints (i.e., aortic
aneurysm repair or dissection, stroke, or death) were
calculated using the Kaplan–Meier method.
RESULTS
Characteristics of the study population
Thirty-three patients with ACTA2 Arg179His (24),
Arg179Cys (7), Arg179Leu (1), or Arg179Ser (1) mutation
were included (including seven previously reported cases1).
Except for one, all patients had de novo mutations. Median
age at diagnosis by genetic testing was 11 years (IQR 15, 0.03–
36). Twenty-one (64%) were females and only 12 were males
(36%). By race or ethnicity, 26 were of European descent, 5
were Asian, 1 was African American, and 1 was Hispanic/
Latino.
Cardiac, aortic, and peripheral arterial complications
All patients had a patent ductus arteriosus (91%) or an
aortopulmonary window (APW; 9%) diagnosed during
infancy (Supplemental Information). PDAs were noted to
be large or aneurysmal and often associated with pulmonary
arterial hypertension. In two patients with PDA, the lesion
was noted to be large or broad-based with an APW
physiology. Twenty-nine patients with available surgical
information had ligation or patch closure of the PDA or
APW; 25% of patients underwent this surgery within the first
month of life, 50% within 2 months, and 90% within
12 months (Table 1). Four patients required re-operations
due to residual shunting. In seven patients, the PDA or APW
was present in the setting of aortic arch obstruction or aortic
coarctation. Eleven patients also had atrial septal defects and
one had a ventricular septal defect.
Twelve patients (36%) had had an aortic event, defined as
an elective aortic aneurysm repair or dissection, at median age
of 14 years (IQR 7, 10–25; Table 1). Cumulative risk of aortic
event was 100% by the age of 25 years (Figure 1a). In seven
patients, this first event was elective repair of an ascending
aortic aneurysm, involving the aortic root and arch. Two
children, ages 10 and 12 years, had repair at 42 mm (z-score
7.8) and 49 mm (z-score 8.1), respectively, and two adults, age
24 and 25 years, had repair at 55 mm (z-score not available)
and 58 mm (z-score 8.1), respectively. Three patients had
valve-replacing aortic root replacement, three had valve-
sparing aortic root replacement, and one had an ascending
aortic replacement only. Four of these patients (age 12–25
years) had concomitant total aortic arch replacement.
Two patients had type A aortic dissections at 17 and 24
years of age, and three patients had type B aortic dissections
(DeBakey type IIIA in one and IIIB in two patients), all at the
age of 14 years. One patient with type A dissection was found
to have a chronic dissection of the ascending aorta when she
presented for repair of a 53-mm ascending aortic aneurysm.
One patient had a type B dissection (#18) when he was being
monitored for a 39-mm ascending and 41-mm descending
thoracic aortic dilation. The second patient (#20) developed a
type B dissection within 24 hours after undergoing a second
stage right cerebral revascularization procedure; previous
imaging showed the proximal descending aorta measured
35 mm and the ascending aorta was 63 mm. The dissection
was complicated by occlusion of the superior mesenteric
artery and small bowel ischemia. A stent was placed in the
superior mesenteric artery and the aortic dissection was
medically managed. The patient died 10 days later; autopsy
was not performed. The third patient (#22) with type B
dissection was medically managed and died suddenly 3 years
later of unknown cause after being lost to follow-up.14
Of these 12 patients with prior aortic events, four had a
subsequent aortic aneurysm repair or dissection. One patient
(#31) developed rapid enlargement of her suprarenal
thoracoabdominal aorta from 44 to 50 mm and underwent
open thoracoabdominal repair. The second patient (#32) was
being monitored for an aortic arch aneurysm (48 mm on last
measurement) due to previous strokes with sequela of left
hemiparesis and died of a ruptured type B dissection at the
age of 32 years. The third patient (#29) underwent surgery for
aneurysms of the arch and abdominal aorta at the age of 31
years, and died from postoperative complications. The fourth
patient (#33) underwent open repair of the distal aorta
(details not available). Of the patients who had previous
elective aortic aneurysm repair and no other aortic events
(n = 4), three have thoracoabdominal aortic dilation
(Figure 2).
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The patients with no history of an aortic event (n = 21)
were significantly younger (median age at last follow-up was 5
years, range 0.1–20.5) compared with the median age at first
aortic event in the 12 patients above (P = 0.0007). Of 19
patients who had imaging of the proximal thoracic aorta, 17
(90%) were noted to have dilation of the aortic root and
ascending aorta (n = 9) or the ascending aorta sparing the
aortic root (n = 8). Median maximum diameter of this
segment was 27 mm (range 18–68) at last follow-up. Of 14
patients who had evaluation of the aortic arch and proximal
descending thoracic aorta, four had a dilated aortic arch and
none had a dilated descending aorta. Seven patients who had
evaluation of the distal thoracic and abdominal aorta did not
have dilation of these segments.
Eighteen (54%) patients had peripheral arterial dilation at
median age of 8 years. Sites of arterial dilation include the
proximal internal carotid artery (44%), common carotid (22%),
brachiocephalic (24%), subclavian (12%), axillary (9%), and
external/internal iliac arteries (3%). None of the patients had
other arterial dissection or rupture. Three patients with axillary
artery aneurysms required surgical repair due to acute
thrombosis (Table 1; Supplemental Information). One
patient (#27) has a chronic arteriovenous malformation in the
right forearm. No coronary artery disease has been reported.
Table 1 Individual clinical characteristics and ages at clinical events of the 33 patients with ACTA2 Arg179 alterations
ID ACTA2
variant
Age at
diagnosis
Sex CHD
repair
First
stroke
Cerebral
revascularization
First aortic
event
Second
aortic
event
Other
arterial
eventa
Death or
last f/u
Cause of
deathb
Age Age Age Typec Age Typec Age Age Age
1 R179C 0.4 F 0.10 0.1
2 R179H 0.03 M NA 0.5 4
3 R179H 1 F 0.03 0.1 1.9 4
4 R179C 1.7 F 0.10 2.2
5 R179H 1.5 M 0.17 2.5
6 R179H 2.9 F 0.4d 2.9 2.9
7 R179H 2.3 F 0.05 3.4
8 R179C 3.3 F 0.05d 3.6
9 R179H 3.3 F 0.03 0.006 3.6
10 R179C 4 M 0.02 3.9
11 R179L 5.2 M 0.04 5.2
12 R179C 4.3 F 0.48 4.2 5.6
13 R179H 8 M 0.1d 8
14 R179H 7 F 2.6d 8.7
15 R179H 9 F 0.2d 9.2 9.2
16 R179H 13.0e F 0.1d 9.3 9.4 11.7 9
17 R179H 13.2 F 0.17 13.2 12.9
18 R179H 9.9 M 0.39 B 14.2 11.1 14.2
19 R179H 14.6 M 0.05 6.5 14.1
20 R179H 14.4 M 0.13 1.4 14.4 B 14.5 14.5 9
21 R179H 11.1 F 0.39 R 10.9 16.2
22 R179H 27.5e M 0.25 B 14 17 9
23 R179H 14 F 0.07 18.4
24 R179C 19 F 0.25 19
25 R179H 19 F 0.2d R 15 19.9
26 R179S 16 F 0.86 20.5
27 R179H 16.6 M Unkn. R 12.8 23.8
28 R179H 26.1 F 0.3d A 24.7 26.2
29 R179C 30.4e M 0.2d R 14 R 30.4 30.4 3
30 R179H 29.1 F 0.1d R 24.9 24.2 31.3 4
31 R179H 26.8 F 0.4d 31.5 28.8 R 25.3 R 25.8 27.3 31.6 1
32 R179H 26.4 F 0.3d 16 R 11.7 B 32.7 32.7 2
33 R179H 36.6 M 2 A 17 R 18 37.4
CHD, congenital heart defect (i.e., patent ductus arteriosus, aortopulmonary window); F, female; last f/u, last recorded follow up by a physician; M, male; NA, not
applicable; Unkn., unknown.
All ages are in years
aIncludes other arterial aneurysm repair or thromboembolic event. b1, stroke complications; 2, aortic dissection/rupture; 3, postoperative complications due to aortic sur-
gery; 4, pulmonary-related complications; 9, unknown or undetermined. cR, aortic aneurysm repair; A, type A aortic dissection; B, type B aortic dissection; blank, no
aortic event. dApproximate age. ePostmortem analysis.
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Low blood pressure was common in SMDS patients.
Median systolic blood pressure was 101 mmHg (IQR 15,
58–108, n = 14) among young patients age ≤ 18 years and
was 113 (IQR 41, 80–123, n = 7) among adult patients.
Median diastolic blood pressure was 50 mmHg (IQR 11,
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Figure 1 Cumulative risk of first aortic event, stroke, and death
associated with smooth muscle dysfunction syndrome. CI,
confidence interval.
Figure 2 Reconstructed magnetic resonance angiogram images in a
13-year-old patient with ACTA2 Arg179His alteration. (Top) Dilation
of the aortic root and ascending aorta and bilateral subclavian and
axillary artery aneurysms. (Bottom) Dilation of the descending and
thoracoabdominal aorta.
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23–88) among young patients and 54 mmHg (IQR 22, 40–75)
among adults.
Of 29 patients with detailed records of medications,
medications taken at the last clinical evaluation are shown
in Supplemental Figure 1.
Cerebrovascular complications
Patients with SMDS have distinct cerebrovascular disease,
including dilation of the proximal carotid arteries, widespread
occlusive arteriopathy characterized by moyamoya-like stenotic/
occlusive lesions in the distal internal carotid arteries and its
branches and the posterior circulation, absence of basal
collateral vessels, abnormally straight course of the intracranial
arteries, and periventricular and deep white matter signal
changes on magnetic resonance imaging (MRI).3 Intracranial
artery stenosis or occlusion was present in 23 (77%) patients at
median age of 8 years (IQR 10) and as early as 5 days of age. In
16 (53%) patients, stenosis involved more than one artery,
commonly the distal internal carotid (53%), cerebral (60%),
vertebral (20%), and basilar artery (17%). The majority of
patients (95%) had T2-weighted hyperintense periventricular
white matter changes on brain MRI.
Eight females and one male had cerebral ischemic infarction
at median age of 4 years (IQR 7; Figure 1b). Seven of these
patients presented before 10 years, the youngest of whom was
2 days old with bilateral watershed and basal ganglia
infarction. The other two patients had had previous
composite aortic valve graft replacement (Table 1).15
Five patients underwent cerebral vessel revascularization
involving one (n = 1) or both (n = 4) sides and using indirect
encephaloduroarteriosynangiosis in four patients and both
direct and indirect extracranial to intracranial arterial bypass
procedures in one patient (Table 1). Pre- and postoperative
cerebral imaging was available for three patients that showed
effective collateralization of hypoperfused areas in the middle
cerebral artery territory, predominantly provided by neoform
vessels arising from the middle meningeal artery (Figure 3).
One patient died 3 years later of a stroke, two others died of
unknown causes, and the other two patients continued to have
transient ischemic symptoms.
Six patients (18%), age 1–19 years, had seizures (Supplemental
Information). Four patients had structural brain abnormalities,
most commonly malformation of the corpus callosum described
as thinning or foreshortening. One had colpocephaly and another
had deficiency in development of the rostrum. Areas of
polymicrogyria were noted in two patients. Six patients (19%)
had mild developmental delay and two (7%) had learning
difficulties.
R ICA
R ICA
L ICA L ECA
L ECAL ICA
R ECA
R ECA
R
R
L
L
Pr
e-
re
va
sc
u
la
riz
at
io
n
Po
st
-re
va
sc
u
la
riz
at
io
n
Figure 3 Representative images before (top row) and 1 year after (bottom row) indirect revascularization surgery (dural inversion).
Angiographic images show multiple abnormalities including straightening of cerebral arteries, dilation of the petrous and cavernous portions followed
by severe stenosis of the terminal segment of the right (R) and left (L) internal carotid arteries (ICAs), severe stenosis of the middle and anterior cerebral
arteries (with distal R M1 occlusion), and areas of parenchymal hypoperfusion (dashed circles). Follow-up angiogram a year after surgery showed new
collateral vessels arising from the middle meningeal arteries (arrows) in the watershed regions of hypoperfusion, with concomitant enlargement of the
parent middle meningeal vessel indicating compensatory increased flow, and retrograde flow through the R middle cerebral artery (arrowhead)
supporting hemodynamically significant supply from the donor vessels. Magnetic resonance fluid-attenuated inversion recovery images illustrate white
matter injury and ischemic infarcts at both time points. ECA, external carotid artery.
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Pulmonary complications
Sixteen patients (48%) had a history of pulmonary arterial
hypertension and one patient (#27) required lung transplant
at the age of 18 months. Patient #2 presented with respiratory
distress at birth and a PDA was diagnosed, but not repaired.
He developed severe pulmonary arterial hypertension and
significant parenchymal disease, and died at 6 months of age
after multiple pulmonary hypertensive crises.
Eleven patients (33%) were diagnosed with chronic lung
disease and five other patients with chronic asthma. Seventeen
patients were noted to have dilation of the main pulmonary
artery and/or its branches. Patient #31 underwent plication of
the main pulmonary artery concomitant with aortic root,
ascending and arch replacement. This patient had chronic
pulmonary disease requiring oxygen supplementation and
multiple episodes of right heart failure starting at the age of 29
years, and died at the age of 31 years after hospitalization for
pneumonia complicated by aspiration.
Other complications
All patients had pupillary abnormalities described in the
medical records as fixed or nonreactive pupils (congenital
mydriasis), iris hypoplasia, and/or aniridia or partial aniridia.
Seven patients had retinal artery tortuosity and one was noted
to have small retinal and vitreous hemorrhages. One adult
patient had retinal detachment.
The frequencies of gastrointestinal and urogenital compli-
cations were variable (Table 2).
Pregnancy
One pregnancy was observed in a 26-year-old G4P0030
patient who presented for genetic evaluation at 24 weeks of
gestation due to a history of PDA repair, ascending aortic
aneurysm repair with mechanical aortic valve replacement,
and aortic coarctation repair, and was later diagnosed with
SMDS during pregnancy. She had an unremarkable brain
magnetic resonance angiogram (MRA) and no distal aortic
enlargement. Fetal ultrasound at 32 weeks of gestation showed
mild dilation of the ascending aorta, an enlarged fetal bladder,
and hydronephrosis; testing after birth confirmed the child
had inherited the ACTA2 alteration. Planned Cesarean section
at 37 weeks gestation demonstrated an atonic uterus and
friable tissues during the procedure.
Causes of deaths
Figure 1c shows the risk of death is high among patients
under the age of 18 and over the age of 30 years. Nine (27%)
of the patients died of complications (median age 17 years,
IQR 19, 0.5–32), with three being diagnosed with SMDS after
death (Table 1). Deaths were due to confirmed or probable
aortic dissection (n = 3), postoperative complications of
aortic surgery (1), stroke (1), or pulmonary complications
(3). One patient (#16) died of undetermined causes despite an
autopsy. The oldest living patient in this cohort was 37
years old.
DISCUSSION
Our findings confirm the cardinal features of SMDS are
PDA or APW, thoracic aortic aneurysm and dissection,
Table 2 Prevalence of associated medical problems among
the 33 patients with ACTA2 Arg179 alterations
Medical condition No. of individuals
affected/totala (%)
Ophthalmic problems
Congenital mydriasis 28/33 (85%)
Aniridia 7/33 (21%)
Retinal vessel tortuosity 7/20 (35%)
Retinal detachment 1/33 (3%)
Cardiovascular problems
Patent ductus arteriosus 30/33 (91%)
Aortopulmonary window 3/33 (9%)
Thoracic aortic dissection 5/33 (15%)
Ascending aortic aneurysmb 24/26 (92%)
Peripheral artery aneurysm 18/33 (54%)
Pulmonary artery aneurysm 17/33 (51%)
Tachycardia 6/33 (18%)
Dysautonomia 2/33 (6%)
Neurologic problems
Stroke 9/33 (27%)
Seizure 6/33 (18%)
Lower-extremity spasticity 2/33 (6%)
Upper-extremity spasticity 1/33 (3%)
Hemiparesis 5/33 (16%)
Intracranial artery stenosis 23/30 (77%)
White matter signal changes on MRI 21/22 (95%)
Developmental delay 6/31 (19%)
Learning difficulties 2/27 (7%)
Pulmonary problems
Pulmonary artery hypertension 16/33 (48%)
Emphysema 2/33 (6%)
Chronic lung disease 11/33 (33%)
Asthma 9/33 (27%)
Pneumothorax 1/33 (3%)
Gastrointestinal problems
Gut malrotation 10/33 (30%)
GERD 9/30 (30%)
Chronic constipation 11/30 (37%)
Gall stone or sludge 10/33 (30%)
Urogenital problems
Hypotonic bladder 15/32 (47%)
Prune belly sequence 2/12 (17%)
Hydronephrosis 10/32 (31%)
Hydroureter 2/32 (6%)
Vesicoureteral reflux 5/32 (16%)
Recurrent UTI 12/33 (36%)
Undescended testes 5/10 (50%)
Hydrocele 3/9 (33%)
GERD, gastroesophageal reflux disorder; MRI, magnetic resonance image; UTI,
urinary tract infection.
aDenominator is based on available records. bDenominator includes only patients
with no prior thoracic aortic dissections.
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thoracoabdominal aortic aneurysm, peripheral artery aneur-
ysms, cerebrovascular disease, retinal vessel tortuosity, con-
genital mydriasis, pulmonary artery hypertension, chronic
lung disease, hypotonic bladder, undescended testes, atonic
gravid uterus, gut malrotation, hypoperistalsis, and gall
bladder sludge or cholelithiasis. Congenital mydriasis and
related pupillary abnormalities and PDA or APW were fully
penetrant in infancy. Thoracic aortic and cerebrovascular
disease were fully penetrant with age. Penetrance of the other
complications were variable.
As all patients had a PDA or APW and congenital
mydriasis or related pupil abnormalities, newborns with these
complications with or without the other systemic complica-
tions should raise the suspicion for SMDS and be referred to a
geneticist for evaluation and undergo genetic testing for an
ACTA2 alteration. Complications can present early in life and
require evaluation by multiple specialists (Table 3).
Multidisciplinary care of these patients is recommended
because medications used to treat complications in one
system may aggravate disease in another.
Surveillance and management of SMDS complications
PDA and APW
PDAs were large, and the majority of patients required
surgical correction in the first year of life. Untreated or late
treatment of PDA is associated with progressive respiratory
deterioration, prolonged ventilator support, and death.6,12
Surgical correction of the PDA should be considered in
infants with SMDS, because delaying this surgery has the
potential to escalate the pulmonary arterial hypertension. In
patients who are not candidates for definitive closure of the
PDA due to high pulmonary vascular resistance, partial
closure by surgery or catheterization may be considered,
followed by management with pulmonary vasodilating agents
and complete closure when the vascular resistance
decreases.16
Complications of the aorta and its branches
Ascending aortic dilation was evident even in utero although
no aortic events occurred until the age of 10 years for
ascending aortic aneurysm repair and 14 years for aortic
dissection (type B). Based on these findings and a previous
study,11 the aortic root, ascending aorta, and arch progres-
sively enlarge and may require repair between late childhood
and early adulthood.
Evaluation of the entire aorta at the time of diagnosis is
recommended. Follow-up imaging should be performed by
echocardiography (if the root and ascending aorta are
adequately visualized) or cardiac MRI/MRA with cardiac-
gated sequences for the aortic root. Based on the earliest
clinically significant dilation of the descending thoracic and
abdominal aorta observed in this cohort, surveillance of these
segments should be started at 10 years of age or earlier if
abnormalities were noted on the initial scan.
Patients may benefit from drug treatments that have been
shown to slow aortic growth. In patients with Marfan
syndrome, the standard of care is β-blockade therapy.17
Results of a recent randomized clinical trial have shown that
β-blocker and losartan are equally effective in reducing the
rate of aortic root dilation in patients with Marfan
syndrome.18 There is limited data on the effectiveness of
other drug treatments for aortic disease, and no therapies
Table 3 Recommendations for evaluation and surveillance of patients with smooth muscle dysfunction syndrome
Evaluationa/procedure At initial presentation/diagnosis Routine follow-up
Genetic consultation ✓
Genetic counseling ✓ Late adolescence or early adulthood
Genetic testing ✓
Cardiovascular assessment ✓ Every 6–12 months
Neurological assessment ✓ Every 6–12 months
Pulmonary assessment ✓ As needed
Gastrointestinal assessment ✓ As needed
Urogenital assessment ✓ As needed
Ophthalmology assessment ✓ Every 12 months
Growth and nutritional assessment ✓ Every 12 months during childhood, adolescence
Neurocognitive assessment ✓ Every 12 months during childhood, adolescence
Diagnostic procedures
Transthoracic echocardiogram ✓ Every 6–12 months
MRA of the chest ✓ Every 12 months starting at age 10 years
MRA of the abdomen/pelvis ✓ Every 12 months starting at age 10 years
Upper extremity ultrasound/CTA/MRA ✓ Every 12 months
MRI of the brain with perfusionc ✓ As neededb
MRA of the head and neckd ✓ As neededb
MRA, magnetic resonance angiography; MRI, magnetic resonance imaging. CTA, computed tomography angiography.
aAll patients should have routine standard of care. bAs needed based on neurologist’s assessment. cRapid MRI without sedation is preferred for acute evaluations.
dTranscranial Doppler ultrasound may be able to replace MRA in young children who are asymptomatic.
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have been specifically tested in individuals with ACTA2
mutations. Given the hypotension and steno-occlusive
cerebrovascular disease in these patients, low doses of these
medications should be used initially with close monitoring of
blood pressure and symptoms. Exercise restrictions are
recommended, including avoidance of isometric exercises
and contact sports.
The risks and benefits of elective surgery of the thoracic or
thoracoabdominal aorta in light of the patient’s comorbid
conditions (i.e., cardiac, cerebrovascular, pulmonary disease)
should be carefully considered. Neurosurgical evaluation prior
to surgical intervention may be required to ensure adequacy
of cerebral perfusion while on cardiopulmonary bypass.
When possible, elective aortic root repair should be delayed
in children until the annulus can accommodate an adult-sized
graft. Valve-sparing procedures should be performed to avoid
the increased risk of thromboembolism associated with
mechanical aortic valves. Concomitant aortic arch replace-
ment should be considered because the data collected here
indicate that the arch will enlarge over time. Placement of an
elephant trunk in preparation for a staged procedure should
be considered because the descending or thoracoabdominal
aorta often enlarge over time. Given that a third of patients
with other ACTA2 mutations experienced type A dissections
when the maximum aortic diameter was o50 mm,19 elective
surgical repair should be discussed when the aortic diameter
reaches 45 mm. Limited data on type B dissections indicate
that these were not preceded by significant dilation and
occurred at younger ages compared with type A dissections.
Puberty appears to be a high-risk period for type B dissections
in SMDS patients and occurred only in males in this cohort.
Rate of growth of descending thoracic and thoracoabdominal
aortic aneurysms should be closely monitored because there
was rapid enlargement in patients. In patients who are
suitable candidates for surgery, descending or thoracoabdom-
inal aortic procedures may be electively performed in surgical
centers with experience. Patients with descending thoracic
aortic dissections should be closely monitored, and treatment
individualized. Given the poor outcomes, i.e., aortic rupture
and sudden death, in SMDS patients who had a thoracic
aortic aneurysm greater than 45 mm or a descending aortic
dissection, elective open or endovascular aortic repair should
be considered in these situations when possible.
Peripheral artery aneurysms may present with symptoms
due to local compression of nearby structures, limb ischemia
with thromboembolism, or rupture, although arterial dissec-
tion or rupture has not been observed with SMDS. Baseline
evaluation by ultrasound, computed tomography, or MRA is
recommended to screen for upper-extremity artery aneurysms
or malformations and assess the size and presence of
thrombus. Annual surveillance by ultrasound of asympto-
matic aneurysms should be performed. Surgical repair of
symptomatic, thrombotic, or large aneurysms (>20 mm in
diameter) should be considered.20 Repair with aneurysm
resection and interposition grafting with an autologous vein
or prosthesis is recommended. Given the poor performance of
stent grafts (high mobility, risk of endoleak due to the rich
collaterals of the axillary artery), these should be used only as
a temporizing measure in an unstable patient or a definitive
measure in patients who are unable to tolerate open repair.
The hypotension present in SMDS patients potentially
increases the risk of anesthesia and should be taken into
account during surgical procedures.
Neurologic complications
Cerebrovascular disease, including stenosis or hypoplasia of
arteries and white matter changes, are present as early as the
neonatal period in this study and previous reports.3,7,8,21
Patients have a high risk of vaso-occlusive strokes and
seizures, the majority of which were observed in neonates and
young children. It is not clear whether the seizures were
provoked by small vessel vasculopathy or hypoxic–ischemic
injury. However, chronic hypotension in the setting of
cerebral vasculopathy compromising blood flow and auto-
regulation to the brain are significant risk factors for cerebral
damage in these patients.
A baseline brain MRI and head and neck MRA should be
performed to evaluate the burden of white matter injury,
ischemic–hypoperfusive events, and degree of stenosis, and to
determine future risk of stroke and management to prevent
neurologic complications. Because radiation is a known risk
factor for moyamoya disease,22,23 MRI is recommended instead
of computed tomography. MRI with sedation should be
performed in experienced facilities with adequate equipment
and well-trained personnel.24 When possible, MRI should be
scheduled and coordinated among specialties to maximize the
extent of imaging and reduce the child’s exposure to sedation.
Although disease progression and optimal screening inter-
vals have not been established, periodic screening for
cerebrovascular disease should be considered as part of the
patient’s surveillance. Transcranial Doppler may be useful in
monitoring patients with SMDS, but additional studies are
needed to examine its utility in predicting risk of stroke in
these patients. Conventional catheter angiogram should be
reserved for patients with focal neurologic symptoms or
evidence on MRA or transcranial Doppler of critical or
progressive narrowing of the cerebral arteries.
Patients who had seizures were managed with standard
anticonvulsant therapy. Treatment with aspirin may be
considered in asymptomatic patients with evidence of cerebral
vasculopathy for the prevention of a first stroke.25 Young
children on aspirin should be monitored given the risk of
Reye syndrome. Patients who had prior aortic root repair with
mechanical valve replacement or thromboembolic events
should be monitored and sufficiently anticoagulated. Hemor-
rhagic complications while on anticoagulation therapy have
not been reported in SMDS patients. Patients, especially
young children, should be closely monitored during illness
resulting in low oxygen saturation and acute infections with
fever increasing cerebral metabolic demand. Any sudden
change in neurologic function should be urgently evaluated.
Patients should be counseled about staying sufficiently
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hydrated and taking measures such as sitting or lying down
with the legs elevated if sudden dizziness or lightheadedness
occurs.
Although surgical revascularization is widely used in
patients with symptomatic moyamoya disease,26 a higher rate
of postoperative ischemic stroke was observed in patients with
SMDS compared with those with moyamoya disease.3 Limited
data on three patients who had indirect cerebral revascular-
ization showed formation of collateral vessels and improved
cerebral perfusion, but no overall reduction in risk of stroke
or transient ischemic symptoms.
Finally, a small number of patients were noted to have mild
developmental delay or learning disability, which may be
attributed to cerebral hypoperfusion or infarction, other
medical complications, or frequent hospitalizations early in
life. Routine cognitive and psychological evaluation should be
performed to assess the need for further neurologic evalua-
tion, rehabilitation, and adjustments at school or home.
Pulmonary complications
Pulmonary arterial hypertension in the setting of PDA or
APW have been reported in these patients, as well as asthma
and poorly characterized chronic lung disease. The cause of
the chronic lung disease has not been determined but may be
due to a developmental defect in the lung parenchyma
predisposing to emphysema. Only one patient required lung
transplant due to pulmonary arterial hypertension. Other
patients required supplemental oxygen early in life and one
adult required permanent oxygen supplementation. In addi-
tion, treatment with respiratory tract agents such as
bronchodilator or anti-inflammatory agents was prevalent
across all patient age groups.
Gastrointestinal complications
Gut malrotation or immotility presents early in life and may
require a surgical procedure to correct the intestinal
malrotation. Feeding difficulties and failure to thrive may
require gastric or nasogastric tube feeding to improve
nutrition. Chronic constipation due to gut immotility was
treated with laxatives. Patients who develop gall bladder
sludge or stones may require gall bladder resection. Hepatic
dysfunction was previously reported in two SMDS patients3
but was not observed in this study.
Urogenital complications
Some of the urogenital complications such as enlarged
bladder and hydronephrosis were detected in utero or were
present in infancy. These could lead to urinary tract
complications presenting early in life and resulting in urinary
tract infections. Treatments for hypotonic bladder may
include increased fluid intake, techniques or drugs to trigger
voiding, or surgery.
Ocular complications
Congenital mydriasis is a characteristic feature of SMDS
detectable at birth as described previously.2 Eye complications
have not been reported to lead to vision loss but patients may
have varying degrees of poor vision. Complete eye examina-
tion by an ophthalmologist should be considered to assess
vision and the need for glasses.2 Funduscopic examination
should be considered to assess arterial tortuosity and evolving
complications.
Reproductive complications
Uncorrected cryptorchidism could lead to testicular atrophy
requiring testosterone replacement therapy or azoospermia as
observed in one patient and a previous report.27
Because uterine contraction is smooth muscle dependent,
pregnant women may not be able to generate sufficient force
to deliver vaginally. Given the high risk of aortic dissection or
rupture, stroke, and other vascular complications associated
with SMDS, discussion of these risks and evaluation by a
cardiologist and high-risk obstetrician are strongly recom-
mended before pregnancy. Genetic counseling should be part
of the ongoing care of adolescent and young adult patients to
discuss concerns about inheritance, recurrence risk, and
reproductive options.
Limitations
Undiagnosed cases, including those with either milder or
more severe sequelae who died before diagnosis, were not
captured by this study. Incomplete or variable documentation
of diagnoses and treatments in the medical records may have
underestimated disease prevalence especially of acute or
transient symptoms. Although the findings illustrate the range
of complications associated with SMDS, future studies
focused on defining specific complications, chronic issues,
and quality of life are needed to fully understand SMDS and
the needs of patients and caregivers.
Conclusions
ACTA2 Arg179 alterations cause a chronic condition
presenting in infancy and requiring lifelong surveillance and
treatment. Affected individuals are at risk of acute events due
to aortic dissection or rupture, arterial thrombosis, ischemic
stroke, and pulmonary complications. Multidisciplinary,
coordinated care and surveillance, and timely management
of symptoms are important to reduce the risk of SMDS
complications. Future studies should address optimal imaging
protocols to monitor the vascular disease and identify
therapies to treat the vascular and pulmonary complications
of SMDS.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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